Memorial Sloan-Kettering says that Scher had nothing to do with making the letter public.

FORBES: The Danger In Dendreon

But Hussain, of the University of Michigan, and Howard Scher, of Memorial Sloan-Kettering, both were among the naysayers.

FORBES: Doctor Voices Dendreon Doubts

Dr. Scher said the first patient he treated four and a half years ago is still alive and on the drug.

WSJ: New Medical Strides Against Prostate Cancer

The Cancer Letter, an industry newsletter, obtained a confidential letter Scher sent to the FDA arguing that Provenge should not be approved.

FORBES: Magazine Article

Dr. Scher reported that the 800 patients treated with the drug had a median survival of 18.4 months compared with 13.6 months for those given a placebo.

WSJ: New Medical Strides Against Prostate Cancer

Howard Scher, a veteran of prostate-cancer studies and chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer, agreed to run the research, which began in 2007.

WSJ: New Medical Strides Against Prostate Cancer

One of the "no" votes was Howard Scher, of the Memorial Sloan-Kettering Cancer Center, who has made a career of designing trials to test prostate cancer drugs.

FORBES: The Danger In Dendreon

In response to a previous Forbes story, readers wrote in alleging that Scher's wife works for a hedge fund that might be short Dendreon stock (betting against its rise).

FORBES: Magazine Article